Downregulated TFT sets included targets of the associated proteins RPA1, whose expression is decreased in OA patients, and WRN, which is mutated in Werner’s syndrome and confers early-onset OA risk; as well as PBRM1, which has been implicated in GWAS of OA and regulation of BMP signaling and osteogenic fate determination (Table S5B). The gene discussed is RPA1; the disease is Werner syndrome.